| Sector |
Media & Entertainment
|
Compare with Sector peers |
| Industry |
Film Production, Distribution & Entertainment
|
Compare with Industry peers |
| Website | http://www.mcom18.com | |
| Market Cap | 96.06 Cr. | |
| Enterprise Value(EV) | 98.28 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.19 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | - | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 6.97 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 14.54 | Calculated using Price: 101.32 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.95 Cr. | 9,480,700 Shares |
| FaceValue | 10 | |
| About Madhuveer Com 18 Network Ltd. | ||
| The company is engaged in the Business of Entertainment, Pharma trading and consulting. | ||
| 1 Day |
|
-1.99% |
| 1 Week |
|
-4.32% |
| 1 Month |
|
+27.24% |
| 3 Month |
|
+40.33% |
| 6 Month |
|
+102.11% |
| 1 Year |
|
+468.89% |
| 2 Year |
|
+840.76% |
| 5 Year |
|
+7754.26% |
| 10 Year |
|
+1158.63% |
| 7 years | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 0.12 | 0.24 | 0.14 | -1.55 | 0.02 | 2.44 | 0.16 | |
| Return on Capital Employed (%) | 0.23 | 0.32 | 0.19 | -1.51 | 0.03 | 2.97 | 0.27 | |
| Return on Assets (%) | 0.11 | 0.23 | 0.14 | -1.49 | 0.02 | 2.37 | 0.16 |
| Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | |
| Non Curr. Liab. | 0 | 0 | 0 | ||||||
| Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Minority Int. | |||||||||
| Equity & Liab. | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | |
| Non Curr. Assets | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | |
| Curr. Assets | 5 | 6 | 5 | 6 | 6 | 6 | 6 | 6 | |
| Misc. Exp. not W/O | 0 | ||||||||
| Total Assets | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| PBIDT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | |||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | ||||
| Taxation | 0 | 0 | 0 | ||||||
| Exceptional Items | |||||||||
| PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Minority Interest | |||||||||
| Share Associate | |||||||||
| Other Related Items | |||||||||
| Consolidated Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 6 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash Fr. Inv. | -1 | 0 | 0 | 0 | ||||
| Cash Fr. Finan. | 0 | |||||||
| Net Change | 5 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Mon, 29 Apr 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sagar Samir Shah |
|||||||||||||||||||||
|
Fri, 26 Apr 2024
Compliance Certificate For Period Ended March 31 2024 Compliance Certificate for period ended March 31 2024 |
|||||||||||||||||||||
|
Fri, 26 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Divya Rathi Designation: Company Secretary EmailId: tohealpharmachem@gmail.com Name of the Chief Financial Officer: Punit Bhavsar Designation: Chief Financial Officer EmailId: tohealpharmachem@gmail.com Date: 26/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
| Fri, 26 Apr 2024 |
Opening at High
|
Closing Below Previous Low
|
Closing Below Previous Low for 3 days
|
Making Lower Lows for 3 days
|
Close Within 52 Week High Zone
|
